Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 11, 2023
Event: Entry into a Material Definitive Agreement involving a private placement of a convertible note and warrant.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $4.0 million received from the sale of a $4.3 million convertible note and warrant.
- Debt Instrument: $4.3 million Convertible Note amortizing monthly over 26 months with a 5% annual interest rate.
- Equity Instrument: Warrant to purchase 1,018,079 shares of Common Stock at an exercise price of $2.35 per share (4-year term).
- Conversion Price: Lower of $2.35, 90% of the three lowest daily VWAPs of the 15 trading days prior to payment, or 90% of the VWAP of the trading day prior to payment.
- Placement Agent Fees: $320,000 cash plus a warrant for 71,266 shares (exercise price $2.35).
- Collateral: Investor holds a security interest and lien on all Company assets and intellectual property.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement (SPA) with Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B. Key structural changes include:
- Repayment Flexibility: Monthly amortization payments can be made in cash, registered shares of Common Stock, or a combination, subject to equity conditions.
- Springing Deposit Account Control Agreement (DACA): A separate bank account was established for the Investment Amount. In the event of default, the Investor may assume control of this account to collect remaining amounts owed.
- Registration Rights: The Company must file a resale registration statement effective within 60 days of closing to register shares issuable upon conversion or exercise.
Outlook, Risks, and Contingencies
- Liquidity Risk: The transaction includes a "springing" control agreement over bank accounts, indicating significant leverage and potential liquidity constraints if repayment obligations are not met.
- Dilution Risk: Full exercise of the warrant would yield approximately $2.4 million in additional proceeds but would increase the share count by over 1 million shares.
- Asset Encumbrance: All assets and intellectual property are pledged as collateral until the Note is paid off.
- Management Commentary: The filing does not provide explicit forward-looking guidance beyond the terms of the financing agreement.
Investor Verification Checklist
- Verify the Company's current cash balance and ability to meet monthly amortization payments without immediate equity conversion.
- Review the specific "equity conditions" required to make payments in stock rather than cash.
- Assess the impact of the 5% interest rate and potential conversion discounts on future earnings per share (EPS).
- Confirm the status of the resale registration statement required to be effective within 60 days.
- Monitor the Company's compliance with the Springing DACA to avoid loss of control over operating funds.